

DESCRIPTION

Species Reactivity	Human
Specificity	Detects human FACA/FANCA in direct ELISAs and Western blots. In direct ELISAs, less than 1% cross-reactivity with recombinant mouse FANCA, recombinant human (rh) FANCD2, rhFANCE, rhFANCF, rhFANCG, and rhFANCI is observed.
Source	Polyclonal Goat IgG
Purification	Antigen Affinity-purified
Immunogen	<i>E. coli</i> -derived recombinant human FACA/FANCA Tyr35-Arg142 Accession # O15360
Conjugate	Alexa Fluor 350 Excitation Wavelength: 346 nm Emission Wavelength: 442 nm
Formulation	Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

Western Blot Optimal dilution of this antibody should be experimentally determined.

PREPARATION AND STORAGE

Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied

BACKGROUND

FACA (Fanconi anemia group A) is a 160-165 kDa protein that belongs to Fanconi anemia protein group I. FACA is widely expressed, activated by phosphorylation, partners with FANCG, and participates in the formation of an eight subunit Fanconi anemia core complex that ubiquitinates FANCD2 and FANCI. Ultimately, this contributes to the reactivation of stalled DNA repair replication forks. Human FACA is 1455 amino acids (aa) in length. It contains one NLS (aa 18-34) and four phosphorylation sites at Ser849, 850, 858 and 1449. There are four potential splice variants. One shows a premature truncation after Cys297, a second contains a six aa substitution for aa 297-1455, a third shows a deletion of aa 143-174 accompanied by truncation after Cys297, and a fourth exhibits an alternative start site at Met528, accompanied by a 35 aa substitution for aa 1390-1455. Over aa 35-142, human FACA shares 61% aa identity with mouse FACA.

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.